Fig. 3: GMP iExoKrasG12D in accelerated titration dosing design. | Nature Communications

Fig. 3: GMP iExoKrasG12D in accelerated titration dosing design.

From: Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates

Fig. 3: GMP iExoKrasG12D in accelerated titration dosing design.

Schematic representation of treatment timeline for patients in DL 4: dose level 4, DL 5: dose level 5, and DL5, and DL6: dose level 6, depicting prior therapy, timeframe for iExoKrasG12D therapy, and target lesion progression; scale bar listed. C1D1: Cycle 1 Day 1; C2D1: Cycle 2 Day 1; etc. QW: weekly; Dx: diagnosis; mo: month; Dt: death; [CT]: clinical trial; **: mutation analysis.

Back to article page